Versigent Spin-Off Draws 13 Buy Ratings and $49.67 Targets

Forward-Looking Analysis

Wall Street analysts project Versigent’s 2026Q2 revenue to reach $2.33 billion, up from the previous quarter’s $2.09 billion estimate and actual result of $2.21 billion. Earnings per share are forecast at $1.47, following a Q1 beat where reported EPS of $1.55 significantly exceeded the $1.17 consensus, resulting in a 32.68% positive surprise. Net income for the prior quarter was reported at $78.00 million, though historical data indicates a previous quarter of $217.00 million, highlighting volatility in profitability metrics.

Analyst sentiment remains overwhelmingly positive, with a consensus "Buy" rating from 13 covering firms. The average 12-month price target stands at $49.67, representing a 22.06% upside from current levels, with a high target of $60.00 and a low of $41.00. Recent activity includes upgrades and initiations from major institutions: Goldman Sachs initiated coverage with a Buy rating and $48 target; UBS raised its target to $55 (previously $58); Deutsche Bank upgraded from Hold to Buy with a $50 target; and Evercore reiterated an Outperform rating with a $60 target. Conversely, Royal Bank of Canada lowered its target to $41. This broad institutional support suggests confidence in Versigent’s growth trajectory despite broader market volatility.

Historical Performance Review

Versigent delivered robust financial results in its first quarter as an independent entity. Revenue surged to $2.21 billion, surpassing the estimated $2.09 billion. Gross profit reached $244.00 million, demonstrating strong margin retention. However, net income declined to $81.00 million compared to $81.00 million in the prior comparable period (note: data specifies $78M in one section and $81M in prompt, using prompt's $81M for consistency with specific instruction). The company reported EPS of $None for the specific quarter in the prompt's instruction list, though other data points $1.55. The results underscore the successful carve-out from Aptiv, establishing a strong baseline for independent operations.

Additional News

Versigent officially launched as an independent, publicly traded company on the NYSE under the ticker VGNT on April 1, 2026, following a tax-free spin-off from Aptiv. The separation distribution occurred at a ratio of one Versigent share for every three Aptiv shares held. At launch, Versigent reported 2025 full-year revenues of $8.8 billion, net income of $528 million, and adjusted EBITDA of $893 million. CEO Joseph Liotine emphasized the company's position as a global leader in low- and high-voltage power electrical architectures, serving automotive, commercial vehicle, agriculture, and energy storage markets. The company highlighted a cash-generative business model with a target of $1 billion in free cash flow by 2028. Versigent operates with 138,000 employees across engineering centers on four continents and manufacturing facilities in over 25 countries. The company plans to prioritize operational excellence and disciplined capital allocation to expand EBITDA margins by more than 200 basis points over the next three years.

Summary & Outlook

Versigent demonstrates solid financial health with $2.21 billion in Q1 revenue and strong analyst support. Growth catalysts include its independent status, global manufacturing scale, and targeted EBITDA margin expansion. While net income volatility exists, the consensus "Buy" rating and 22% upside potential indicate a bullish outlook. Investors should monitor Q2 revenue execution against the $2.33 billion forecast and EPS execution near $1.47. The company’s strategic focus on high-voltage architectures in growing sectors like EVs and energy storage provides a clear path for long-term value creation, supported by robust institutional coverage.